Intranasal delivery of ESBA105, a TNF-alpha-inhibitory scFv antibody fragment to the brain

Journal of Neuroimmunology

Volumn 215, Issue 1-2, 2009, Pages 65-72

  Furrer, Esther ^a   Hulmann, Valérie ^a   Urech, David M ^a  

^a ESBATech AG   (Switzerland)

Author keywords

CNS delivery; Intranasal; Local TNF inhibition; Neurodegenerative disease; Pharmacokinetics; Single chain antibody fragment

Indexed keywords

ESBA 105; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BRAIN STEM; CEREBELLUM; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EXPOSURE; DRUG PENETRATION; DRUG TRANSPORT; FEASIBILITY STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; OLFACTORY BULB; PRIORITY JOURNAL; SYSTEMIC THERAPY; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODY AFFINITY; BRAIN; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOGLOBULIN FRAGMENTS; MALE; MICE; MICE, INBRED BALB C; TISSUE DISTRIBUTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70349728821     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2009.08.005     Document Type: Article

References (47)

1. Balin B.J., Broadwell R.D., Salcman M., and el-Kalliny M. Avenues for entry of peripherally administered protein to the central nervous system in mouse, rat, and squirrel monkey. J. Comp. Neurol. 251 (1986) 260-280
2. Banks W.A. Developing drugs that can cross the blood-brain barrier: applications to Alzheimer's disease. BMC Neurosci. 9 Suppl 3 (2008) S2
3. Banks W.A., Terrell B., Farr S.A., Robinson S.M., Nonaka N., and Morley J.E. Passage of amyloid beta protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease. Peptides 23 (2002) 2223-2226
4. Beck J., Rondot P., Catinot L., Falcoff E., Kirchner H., and Wietzerbin J. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations?. Acta Neurol. Scand. 78 (1988) 318-323
5. Benedict C., Hallschmid M., Hatke A., Schultes B., Fehm H.L., Born J., and Kern W. Intranasal insulin improves memory in humans. Psychoneuroendocrinology 29 (2004) 1326-1334
6. Born J., Lange T., Kern W., McGregor G.P., Bickel U., and Fehm H.L. Sniffing neuropeptides: a transnasal approach to the human brain. Nat. Neurosci. 5 (2002) 514-516
7. Capsoni S., Giannotta S., and Cattaneo A. Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 12432-12437
8. Chung Y.B., Han K., Nishiura A., and Lee V.H. Ocular absorption of Pz-peptide and its effect on the ocular and systemic pharmacokinetics of topically applied drugs in the rabbit. Pharm. Res. 15 (1998) 1882-1887
9. De Rosa R., Garcia A.A., Braschi C., Capsoni S., Maffei L., Berardi N., and Cattaneo A. Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 3811-3816
10. Dhanda D.S., Frey II W.H., Leopold D., and Kompella U.B. Approaches for drug deposition in the human olfactory epithelium. Drug Deliv. Technol. 5 4 (2005)
11. Eyles J.E., Williamson E.D., and Alpar H.O. Immunological responses to nasal delivery of free and encapsulated tetanus toxoid: studies on the effect of vehicle volume. Int. J. Pharm. 189 (1999) 75-79
12. Francis G., Martinez J., Liu W., Nguyen T., Ayer A., Fine J., Zochodne D., Hanson L.R., Frey II W.H., and Toth C. Intranasal insulin ameliorates experimental diabetic neuropathy. Diabetes 58 (2009) 934-945
13. Frey II W.H. Bypassing the blood-brain barrier to deliver therapeutic agents to the brain and spinal cord. Drug Deliv. Technol. 2 5 (2002)
14. Fromont A., De Seze J., Fleury M.C., Maillefert J.F., and Moreau T. Inflammatory demyelinating events following treatment with anti-tumor necrosis factor. Cytokine 45 (2009) 55-57
15. Furrer E., Berdugo M., Stella C., Behar-Cohen F., Gurny R., Feige U., Lichtlen P., and Urech D.M. Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-alpha single-chain antibody, upon topical administration to the rabbit eye. Invest. Ophthalmol. Vis. Sci. 50 (2009) 771-778
16. Gross E.A., Swenberg J.A., Fields S., and Popp J.A. Comparative morphometry of the nasal cavity in rats and mice. J. Anat. 135 (1982) 83-88
17. Hofman F.M., Hinton D.R., Johnson K., and Merrill J.E. Tumor necrosis factor identified in multiple sclerosis brain. J. Exp. Med. 170 (1989) 607-612
18. Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur. J. Pharm. Sci. 11 (2000) 1-18
19. Katsuse O., Iseki E., and Kosaka K. Immunohistochemical study of the expression of cytokines and nitric oxide synthases in brains of patients with dementia with Lewy bodies. Neuropathology 23 (2003) 9-15
20. Keating G.M., and Perry C.M. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis. Biodrugs 16 (2002) 111-148
21. Klavinskis L.S., Barnfield C., Gao L., and Parker S. Intranasal immunization with plasmid DNA-lipid complexes elicits mucosal immunity in the female genital and rectal tracts. J. Immunol. 162 (1999) 254-262
22. Lundholm P., Asakura Y., Hinkula J., Lucht E., and Wahren B. Induction of mucosal IgA by a novel jet delivery technique for HIV-1 DNA. Vaccine 17 (1999) 2036-2042
23. Ma Y.-P., Ma M.-M., Ge S., Guo R.-B., Zhang H.-J., Frey II W.H., Xu G.-L., and Liu X.-F. Intranasally delivered TGF-beta1 enters brain and regulates gene expressions of its receptors in rats. Brain Res. Bull. 74 (2007) 271-277
24. Ma M., Ma Y., Yi X., Guo R., Zhu W., Fan X., Xu G., Frey II W.H., and Liu X. Intranasal delivery of transforming growth factor-beta1 in mice after stroke reduces infarct volume and increases neurogenesis in the subventricular zone. BMC Neurosci. 9 (2008) 117-126
25. Maimone D., Gregory S., Arnason B.G., and Reder A.T. Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J. Neuroimmunol. 32 (1991) 67-74
26. Mogi M., Harada M., Riederer P., Narabayashi H., Fujita K., and Nagatsu T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci. Lett. 165 (1994) 208-210
27. MSStudyGroup. TNF neutralization in MS results of a randomized, placebo-controlled multicenter study. Neurology (1999) 457-465
28. Nagatsu T., Mogi M., Ichinose H., and Togari A. Changes in cytokines and neurotrophins in Parkinson`s disease. J. Neural. Transm. [Suppl.] 60 (2000) 277-290
29. Ottiger M., Thiel M.A., Feige U., Lichtlen P., and Urech D.M. Efficient intraocular penetration of topical anti-TNF-alpha single-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancer. Invest. Ophthalmol. Vis. Sci. 50 (2009) 779-786
30. Reilly R.M., Sandhu J., Alvarez-Diez T.M., Gallinger S., Kirsh J., and Stern H. Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions. Clin. Pharmacokinet. 28 (1995) 126-142
31. Rieckmann P., Albrecht M., Kitze B., Weber T., Tumani H., Broocks A., Luer W., Helwig A., and Poser S. Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann. Neurol. 37 (1995) 82-88
32. Ruddle N.H., Bergman C.M., McGrath K.M., Lingenheld E.G., Grunnet M.L., Padula S.J., and Clark R.B. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J. Exp. Med. 172 (1990) 1193-1200
33. Selmaj K., Raine C.S., Cannella B., and Brosnan C.F. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J. Clin. Invest. 87 (1991) 949-954
34. Sharief M.K., and Hentges R. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N. Engl. J. Med. 325 (1991) 467-472
35. Sicotte N.L., and Voskuhl R.R. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 57 (2001) 1885-1888
36. Thorne R.G., and Frey II W.H. Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin. Pharmacokinet. 40 (2001) 907-946
37. Thorne R.G., Pronk G.J., Padmanabhan V., and Frey II W.H. Delivery of insulin-like growth factor I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 127 (2004) 481-496
38. Thorne R.G., Hanson L.R., Ross T.M., Tung D., and Frey II W.H. Delivery of interferon-beta to the monkey nervous system following intranasal administration. Neuroscience 152 (2008) 785-797
39. Thurber G.M., and Wittrup K.D. Quantitative spatiotemporal analysis of antibody fragment diffusion and endocytic consumption in tumor spheroids. Cancer Res. 68 (2008) 3334-3341
40. Tobinick E.L., and Gross H. Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease. BMC Neurol. 8 (2008) 27-35
41. Tobinick E., Gross H., Weinberger A., and Cohen H. TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study. MedGenMed 8 (2006) 25
42. Trolle S., Chachaty E., Kassis-Chikhani N., Wang C., Fattal E., Couvreur P., Diamond B., Alonso J., and Andremont A. Intranasal immunization with protein-linked phosphorylcholine protects mice against a lethal intranasal challenge with streptococcus pneumoniae. Vaccine 18 (2000) 2991-2998
43. Urech, D.M., Feige, U., Ewert, S., Schlosser, V., Ottiger, M., Polzer, K., Schett, G., Lichtlen, P., 2009. Anti-inflammatory and cartilage-protecting effects of an intra-articularly injected anti-TNF-{alpha} scFv (ESBA105) designed for local therapeutic use. Ann Rheum Dis., Electronic publication ahead of print.
44. Xiao B.G., Bai X.F., Zhang G.X., and Link H. Suppression of acute and protracted-relapsing experimental allergic encephalomyelitis by nasal administration of low-dose IL-10 in rats. J Neuroimmunol 84 (1998) 230-237
45. Yang J.P., Liu H.J., Cheng S.M., Wang Z.L., Cheng X., Yu H.X., and Liu X.F. Direct transport of VEGF from the nasal cavity to brain. Neurosci. Lett. 449 (2009) 108-111
46. Yen W.-C., and Lee V.H.L. Paracellular transport of a proteolytically labile pentapeptide across the colonic and other intestinal segments of the albino rabbit: implications for peptide drug design. J. Control. Release 28 (1994) 97-109
47. Yen W.-C., and Lee V.H.L. Penetration enhancement effect of Pz-peptide, a paracellularly transported peptide, in rabbit intestinal segments and Caco-2 cell monolayers. J. Control. Release 36 (1995) 25-37